Validated Outcome Measures That Tell You Whether Your Program Is Working
The PHQ-9 (Patient Health Questionnaire-9) and GAD-7 (Generalized Anxiety Disorder-7) are the gold-standard validated instruments for depression and anxiety severity measurement. When tracked longitudinally — at intake, 30, 60, and 90 days — they provide the only objective evidence of whether a treatment protocol is producing clinical response.
Vizier tracks PHQ-9 and GAD-7 scores at the individual patient level and aggregates them across your program — showing mean score at intake, proportion achieving clinical response (5+ point reduction), proportion achieving remission (PHQ-9 below 5), and dropout rates at each assessment interval. When a therapist's 90-day response rate is 38% against a program average of 61%, that is a caseload complexity or protocol question that deserves investigation.
Age-stratified analysis shows that 42% of new behavioral health diagnoses fall in the 25–45 age range — the highest-demand cohort — with anxiety disorders (GAD, panic disorder, PTSD) outpacing depressive disorders in this group by approximately 1.3:1 since 2022. Program capacity planning that ignores this distribution risks building capacity for the wrong diagnosis mix.
7-Day Follow-Up After Mental Health Hospitalization — A Measure That Predicts Readmission
The HEDIS FUH (Follow-Up After Hospitalization for Mental Illness) measure tracks whether patients receive a follow-up appointment within 7 days and within 30 days of discharge from an inpatient psychiatric stay. The national average for 7-day follow-up is 38.9% — meaning more than 6 in 10 patients who are discharged from psychiatric hospitalization do not see a behavioral health provider within a week.
Research consistently shows that the 7-day post-discharge period carries the highest readmission risk. Programs that fail this measure are not just missing a HEDIS point — they are failing the patients most likely to return to the ED within 30 days. Vizier tracks every inpatient psychiatric discharge in your data, flags patients who have not had a follow-up appointment scheduled, and shows you the contact-to-appointment conversion rate by outreach method.
Telehealth Adoption Stabilized — Understanding the Mix That Drives Outcomes
Behavioral health telehealth utilization peaked at 64% of all outpatient visits in Q2 2020 and stabilized at approximately 38–42% by 2024 for most programs. The appropriate mix depends on diagnosis, severity, and patient population — telehealth shows strong outcomes for mild-to-moderate anxiety and depression, while in-person care remains preferred for severe depression, psychosis, and substance use disorder treatment.
Vizier tracks your telehealth vs. in-person split by diagnosis group, provider, and patient age — and correlates the delivery mode with completion rates, no-show rates, and PHQ-9 trajectory outcomes. Understanding which patient segments have better outcomes via telehealth allows your program to design access pathways that match modality to need.
MOUD Retention, Crisis Utilization, and Program Outcome Measurement
Medications for Opioid Use Disorder (buprenorphine, methadone, naltrexone) show the strongest evidence base in addiction medicine — but only when retention in treatment exceeds 90 days. Vizier tracks MOUD retention rates at 30, 60, 90, and 180 days, dropout timing, and correlates retention with prescription fill data and appointment attendance.
Crisis line call volume, ED psychiatric visit rates, and mobile crisis response utilization are demand signals for capacity planning. Vizier tracks crisis utilization by hour of day, day of week, and ZIP code — enabling staffing alignment to demand patterns. 988 Lifeline call volumes in your service area inform whether community crisis capacity is meeting need.
Post-COVID behavioral health demand is concentrated in the 25–45 cohort (42% of diagnoses) with a secondary peak in adolescents 13–18. Patients aged 65+ are significantly underdiagnosed — late-life depression affects 15–20% of this population but is screened at rates below 40% in primary care. Stratified demand data drives accurate capacity planning.
Behavioral Health Data Across the Care Continuum
FAQ
Behavioral Health Director Questions on Outcomes, FUH, and Parity
How does Vizier track PHQ-9 trajectory at the patient level?+
Vizier captures every PHQ-9 score from the EHR — typically as an observation in the assessments module or a structured encounter form — and produces a trajectory chart per patient: initial score, follow-up scores, and a clinical interpretation (minimal, mild, moderate, moderately severe, severe). Patients with worsening trajectory or sustained PHQ-9 ≥15 are surfaced to care managers. The same logic applies to GAD-7, PCL-5, and AUDIT.
How does Vizier compute HEDIS FUH (Follow-Up after Hospitalization for Mental Illness)?+
FUH measures the percentage of discharges from inpatient psychiatric hospitalization for which the patient had a follow-up visit with a mental health provider within 7 days (7-day rate) and 30 days (30-day rate). National 7-day rate is approximately 38.9%. Vizier identifies discharges, looks for qualifying follow-up encounters within the window, and flags discharges at risk of missing the threshold while the window is still open.
Can Vizier track MOUD (Medication for Opioid Use Disorder) retention?+
Yes. Vizier computes retention for buprenorphine, methadone, and naltrexone treatment as the percentage of patients still active at 30, 90, 180, and 365 days from initiation. The 6-month retention benchmark is 40–60% depending on population. The platform surfaces patients with gaps in medication pickup (from pharmacy claims) or missed visits, both of which are predictive of treatment discontinuation.
How does Vizier support mental health parity compliance reporting?+
Mental Health Parity and Addiction Equity Act (MHPAEA) compliance requires comparable treatment limits, network adequacy, and authorization processes for behavioral health vs. medical/surgical benefits. Vizier reports prior authorization denial rates, network adequacy metrics, and visit limits applied to BH services compared to medical/surgical equivalents — the data set most commonly requested in parity audits.
Does Vizier handle 42 CFR Part 2 confidentiality for SUD records?+
Yes. Vizier supports segregation of substance use disorder records under 42 CFR Part 2, which has tighter consent requirements than HIPAA. Records identified as Part 2-protected can be excluded from non-consented analytics views and audited separately. The platform handles 42 CFR Part 2 amendments under the 2024 Final Rule that aligned several Part 2 provisions with HIPAA.
Can Vizier model demand surge and capacity allocation?+
Yes. Vizier tracks new BH diagnoses by age stratum, diagnosis category, and referral source with month-over-month and year-over-year trend lines. The 42% increase in BH diagnoses since 2020 has not been uniform — the 25–45 cohort drove disproportionate volume in the post-COVID surge. Vizier surfaces where demand is concentrating so capacity (telehealth slots, in-person slots, MOUD inductions) can be allocated where the gap is largest.
Measure What Your Program Is Producing
Upload behavioral health encounter data and see PHQ-9 trajectories, follow-up compliance rates, and age-stratified demand analysis — without a data team or a six-month implementation.